Colony Group LLC lessened its holdings in VWR Corp (NASDAQ:VWR) by 5.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 136,806 shares of the medical research company’s stock after selling 7,385 shares during the quarter. Colony Group LLC owned approximately 0.10% of VWR worth $4,530,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Schroder Investment Management Group increased its position in VWR by 0.6% during the 3rd quarter. Schroder Investment Management Group now owns 2,987,927 shares of the medical research company’s stock valued at $98,871,000 after purchasing an additional 18,316 shares during the period. SG Americas Securities LLC increased its position in VWR by 1,089.9% during the 3rd quarter. SG Americas Securities LLC now owns 191,283 shares of the medical research company’s stock valued at $6,333,000 after purchasing an additional 175,208 shares during the period. Aperio Group LLC increased its position in VWR by 7.5% during the 3rd quarter. Aperio Group LLC now owns 53,329 shares of the medical research company’s stock valued at $1,766,000 after purchasing an additional 3,721 shares during the period. Amalgamated Bank increased its position in VWR by 37.9% during the 2nd quarter. Amalgamated Bank now owns 15,445 shares of the medical research company’s stock valued at $510,000 after purchasing an additional 4,243 shares during the period. Finally, Crossmark Global Holdings Inc. acquired a new stake in VWR during the 3rd quarter valued at approximately $318,000. Institutional investors and hedge funds own 96.66% of the company’s stock.
Shares of VWR Corp (NASDAQ VWR) opened at $33.25 on Tuesday. The company has a market cap of $4,380.00 and a P/E ratio of 17.32. VWR Corp has a 52-week low of $24.42 and a 52-week high of $37.25. The company has a current ratio of 1.25, a quick ratio of 0.79 and a debt-to-equity ratio of 1.09.
VWR (NASDAQ:VWR) last announced its quarterly earnings data on Tuesday, November 7th. The medical research company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.46 by $0.08. The company had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.16 billion. VWR had a net margin of 4.11% and a return on equity of 11.79%. The company’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.44 EPS. research analysts expect that VWR Corp will post 1.85 earnings per share for the current year.
A number of analysts have weighed in on the stock. ValuEngine downgraded shares of VWR from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. BidaskClub raised shares of VWR from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 23rd. Finally, Zacks Investment Research downgraded shares of VWR from a “buy” rating to a “hold” rating in a research report on Thursday, September 14th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $31.67.
VWR Company Profile
VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC.
Receive News & Ratings for VWR Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VWR Corp and related companies with MarketBeat.com's FREE daily email newsletter.